Beam Therapeutics, Inc. (BEAM)
24.05
-0.51
(-2.08%)
USD |
NASDAQ |
Oct 23, 16:00
24.03
-0.02
(-0.08%)
After-Hours: 20:00
Beam Therapeutics Enterprise Value : 1.578B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 1.578B |
| October 22, 2026 | 1.631B |
| October 21, 2026 | 1.660B |
| October 20, 2026 | 1.669B |
| October 19, 2026 | 1.592B |
| October 16, 2026 | 1.518B |
| October 15, 2026 | 1.648B |
| October 14, 2026 | 1.537B |
| October 13, 2026 | 1.617B |
| October 12, 2026 | 1.689B |
| October 09, 2026 | 1.748B |
| October 08, 2026 | 1.635B |
| October 07, 2026 | 1.652B |
| October 06, 2026 | 1.700B |
| October 05, 2026 | 1.745B |
| October 02, 2026 | 1.624B |
| October 01, 2026 | 1.613B |
| September 30, 2026 | 1.619B |
| September 29, 2026 | 1.626B |
| September 28, 2026 | 1.597B |
| September 25, 2026 | 1.601B |
| September 24, 2026 | 1.641B |
| September 23, 2026 | 1.611B |
| September 22, 2026 | 1.772B |
| September 21, 2026 | 1.703B |
| Date | Value |
|---|---|
| September 18, 2026 | 1.671B |
| September 17, 2026 | 1.642B |
| September 16, 2026 | 1.480B |
| September 15, 2026 | 1.492B |
| September 14, 2026 | 1.585B |
| September 11, 2026 | 1.572B |
| September 10, 2026 | 1.611B |
| September 09, 2026 | 1.694B |
| September 08, 2026 | 1.865B |
| September 04, 2026 | 2.157B |
| September 03, 2026 | 2.137B |
| September 02, 2026 | 2.119B |
| September 01, 2026 | 2.091B |
| August 31, 2026 | 2.134B |
| August 28, 2026 | 2.122B |
| August 27, 2026 | 2.242B |
| August 26, 2026 | 2.212B |
| August 25, 2026 | 2.299B |
| August 24, 2026 | 2.020B |
| August 21, 2026 | 2.168B |
| August 20, 2026 | 2.026B |
| August 19, 2026 | 2.096B |
| August 18, 2026 | 1.838B |
| August 17, 2026 | 1.893B |
| August 14, 2026 | 1.857B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Intellia Therapeutics, Inc. | 1.205B |
| Twist Bioscience Corp. | 8.696B |
| Prime Medicine, Inc. | 680.71M |
| Sarepta Therapeutics, Inc. | 2.130B |
| Q32 Bio, Inc. | 104.35M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -122.68M |
| Revenue (Quarterly) | 0.49M |
| Total Expenses (Quarterly) | 123.17M |
| EPS Diluted (Quarterly) | -1.176 |
| Gross Profit Margin (Quarterly) | -1.00K% |
| Profit Margin (Quarterly) | -25.04K% |
| Earnings Yield | -3.58% |
| Normalized Earnings Yield | -3.526 |